We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.

Delisted

AVEO was delisted on the 19th of January, 2023.

76 hedge funds and large institutions have $101M invested in AVEO Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

68% more capital invested

Capital invested by funds: $60.4M → $101M (+$40.9M)

38% more call options, than puts

Call options by funds: $7.28M | Put options by funds: $5.28M

17% more funds holding

Funds holding: 6576 (+11)

11% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 19

Holders
76
Holders Change
+11
Holders Change %
+16.92%
% of All Funds
1.33%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
21
Reduced
19
Closed
9
Calls
$7.28M
Puts
$5.28M
Net Calls
+$2M
Net Calls Change
+$2.03M
Name Holding Trade Value Shares
Change
Change in
Stake
WA
76
WealthTrust Axiom
Pennsylvania
-$128K -22,347 Closed
HSBC Holdings
77
HSBC Holdings
United Kingdom
-$125K -21,897 Closed
WG
78
Winton Group
United Kingdom
-$111K -19,235 Closed
CH
79
CVI Holdings
Delaware
-$76K -13,171 Closed
KAS
80
Kestra Advisory Services
Texas
-$70K -12,200 Closed
SSA
81
Schonfeld Strategic Advisors
New York
-$65K -11,200 Closed
TWM
82
Tradition Wealth Management
Minnesota
-$1K -233 Closed
CA
83
Centerpoint Advisors
Massachusetts
+$431 +50 New

AVEO Hedge Fund Activity: Q1 2021 in Review

76 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2021, worth a combined $101M — up 68% from $60.4M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AVEO positions and 9 closed out — a net gain of 11 holders — while 21 added to existing stakes and 19 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $12.9M. The largest seller was Sectoral Asset Management, cutting an estimated $9.71M.

  • 76 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2021, up from 65 in Q4 2020.
  • Funds reported $101M of AVEO Pharmaceuticals, Inc. stock for Q1 2021, up 68% quarter-over-quarter.
  • 20 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2021 and 9 closed out, a net change of +11 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2021 was Cormorant Asset Management, an estimated $12.9M added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q1 2021 was Sectoral Asset Management, an estimated $9.71M sold.

Based on aggregated 13F filings for Q1 2021.